Bridgeway Capital Management’s ADMA Biologics ADMA Stock Holding History

Bridgeway Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,100	Closed	-$46.9K	–	1357
2023 Q3	$46.9K	Hold	13,100	–	–	﹤0.01%	1310
2023 Q2	$48.3K	Sell	13,100 -1,580,000	-99%	-$5.86M	﹤0.01%	1333
2023 Q1	$5.27M	Sell	1,593,100 -1,046,000	-40%	-$3.62M	0.14%	239
2022 Q4	$10.2M	Buy	2,639,100 +188,800	+8%	+$582K	0.27%	77
2022 Q3	$5.95M	Buy	2,450,300 +2,187,200	+831%	+$5.25M	0.16%	210
2022 Q2	$521K	Hold	263,100	–	–	0.01%	867
2022 Q1	$481K	Buy	263,100 +250,000	+1,908%	+$390K	0.01%	947
2021 Q4	$18K	Sell	13,100 -250,000	-95%	-$329K	﹤0.01%	1255
2021 Q3	$297K	Sell	263,100 -100,000	-28%	-$140K	0.01%	1160
2021 Q2	$581K	Sell	363,100 -180,000	-33%	-$317K	0.01%	1023
2021 Q1	$956K	Buy	+543,100	New	+$1.24M	0.02%	879

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bridgeway Capital Management's ADMA Position: Q4 2023 in Review

Bridgeway Capital Management sold out of ADMA Biologics (ADMA) in Q4 2023, closing a stake of 13,100 shares — an estimated $46.9K sold.

Bridgeway Capital Management first reported a position in ADMA in Q1 2021 and held it in 11 quarters. The position peaked at $10.2M in Q4 2022. 184 funds tracked by Wall St. Rank hold ADMA as of Q4 2023.

Bridgeway Capital Management reported no remaining ADMA Biologics position as of Q4 2023 after selling out during the quarter.
Bridgeway Capital Management sold 13,100 ADMA Biologics shares in Q4 2023, an estimated $46.9K.
Bridgeway Capital Management first reported a position in ADMA Biologics in Q1 2021 and held it in 11 quarters.
Bridgeway Capital Management's ADMA Biologics position peaked at $10.2M in Q4 2022.
184 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.